# Mycovia Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mycovia-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Durham, US
- Website: www.viamet.com
- Total disclosed funding: $93M
- Latest round: Series D (Oct 21, 2014)
- Investors on record: 9

## About

Mycovia Pharmaceuticals focuses on developing innovative treatments for serious fungal infections, utilizing advanced biotechnology to enhance patient care and address unmet medical needs.Mycovia Pharmaceuticals, founded in 2005 and headquartered in Durham, US, specializes in antifungal therapies. The company underwent a significant transition in January 2018 when NovaQuest Capital Management acquired Viamet Pharmaceuticals, Inc., leading to its rebranding. Mycovia has successfully completed 11 deals, with its most recent funding round being Series D, raising USD 60.00 mn from prominent investors including Astellas Venture Management and Novartis Venture Fund.Mycovia Pharmaceuticals offers a range of advanced treatments targeting serious fungal infections. Their key product includes a novel antifungal therapy developed to improve treatment outcomes in patients with challenging infections. The company primarily serves healthcare institutions, aiming to provide effective solutions that enhance patient care in North America and select international markets.Mycovia Pharmaceuticals generates revenue through partnerships and service agreements centered around its innovative antifungal therapies. These agreements typically encompass ongoing support and maintenance services, establishing a recurring revenue model that aligns with client needs in the healthcare sector. The company focuses on delivering value through its specialized treatment offerings.Mycovia Pharmaceuticals is focused on expanding its product line with upcoming treatments for various fungal infections, with anticipated launches in late 2024. The company plans to penetrate new markets in Europe and Asia by 2025, utilizing its recent Series D funding of USD 60.00 mn to support these initiatives. This funding will help accelerate product development and expand their market presence.

## Funding rounds

- Series D, Oct 21, 2014, $60M — Intersouth Partners, Novartis Venture Fund, Lilly Ventures, Astellas Venture Management, Hatteras Venture Partners, Lurie Investments, Woodford Patient Capital Trust, Brandon Point Industries Limited
- Series B, Feb 18, 2011, $15M — Intersouth Partners, Lilly Ventures, Astellas Venture Management, Hatteras Venture Partners, Lurie Investments, Headland Ventures
- Series B, Jun 23, 2009, $10M — Intersouth Partners, Novartis Venture Fund, Lilly Ventures, Astellas Venture Management, Hatteras Venture Partners, Lurie Investments
- Series A, Aug 25, 2008, $3M — Intersouth Partners, Hatteras Venture Partners
- Series A, Oct 22, 2007, $1M — Intersouth Partners, Astellas Venture Management, Hatteras Venture Partners, Lurie Investments
- Series A, Aug 3, 2007, $2.2M — Intersouth Partners, Hatteras Venture Partners
- Series A, Jun 5, 2007, $1M — Intersouth Partners, Astellas Venture Management, Hatteras Venture Partners, Lurie Investments
- Seed, Sep 15, 2006, $0.3M — Intersouth Partners
- Seed, Feb 7, 2006, $0.3M — Intersouth Partners
- Seed, Aug 16, 2005, $0.1M — Intersouth Partners

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Seed, Series A, Series B, Series D
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A, Series B, Series D
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B, Series D
- Lurie Investments — Series A, Series B, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series D
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series B, Series D
- Headland Ventures (https://capitalatlas.ai/funds/headland-ventures) — Series B
- Woodford Patient Capital Trust — Series D
- Brandon Point Industries Limited — Series D